Biomm S.A (BIOM3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomm S.A (BIOM3) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$-46.72 Million ≈ $-9.17 Million USD) by net assets (R$284.10 Million ≈ $55.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIOM3 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Biomm S.A - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Biomm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomm S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomm S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Home Center Holdings Co.Ltd
KQ:060560
|
0.000x |
|
JCY International Bhd
KLSE:5161
|
0.086x |
|
Twelve Seas Investment Co II
NASDAQ:TWLV
|
-0.001x |
|
KEFI GOLD COPPER LS -001
F:KMSA
|
N/A |
|
The ONE Enterprise Public Company Limited
BK:ONEE-R
|
N/A |
|
1RT Acquisition Corp.
NASDAQ:ONCH
|
0.026x |
|
Singer Thailand Public Company Limited
BK:SINGER-R
|
0.006x |
|
JADESTONE ENERGY LS -001
F:8KW
|
N/A |
Annual Cash Flow Conversion Efficiency for Biomm S.A (2006–2024)
The table below shows the annual cash flow conversion efficiency of Biomm S.A from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Biomm S.A (BIOM3) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$262.78 Million ≈ $51.56 Million |
R$-91.84 Million ≈ $-18.02 Million |
-0.350x | +42.54% |
| 2023-12-31 | R$122.94 Million ≈ $24.12 Million |
R$-74.78 Million ≈ $-14.67 Million |
-0.608x | -53.63% |
| 2022-12-31 | R$159.11 Million ≈ $31.22 Million |
R$-63.00 Million ≈ $-12.36 Million |
-0.396x | +52.89% |
| 2021-12-31 | R$111.59 Million ≈ $21.90 Million |
R$-93.78 Million ≈ $-18.40 Million |
-0.840x | -66.12% |
| 2020-12-31 | R$191.48 Million ≈ $37.57 Million |
R$-96.87 Million ≈ $-19.01 Million |
-0.506x | -0.11% |
| 2019-12-31 | R$153.56 Million ≈ $30.13 Million |
R$-77.61 Million ≈ $-15.23 Million |
-0.505x | -21.54% |
| 2018-12-31 | R$106.09 Million ≈ $20.82 Million |
R$-44.12 Million ≈ $-8.66 Million |
-0.416x | +54.67% |
| 2017-12-31 | R$59.30 Million ≈ $11.64 Million |
R$-54.41 Million ≈ $-10.68 Million |
-0.917x | -58.00% |
| 2016-12-31 | R$65.93 Million ≈ $12.94 Million |
R$-38.28 Million ≈ $-7.51 Million |
-0.581x | -380.95% |
| 2015-12-31 | R$115.13 Million ≈ $22.59 Million |
R$-13.90 Million ≈ $-2.73 Million |
-0.121x | +34.64% |
| 2014-12-31 | R$107.10 Million ≈ $21.02 Million |
R$-19.78 Million ≈ $-3.88 Million |
-0.185x | -91.50% |
| 2013-12-31 | R$108.94 Million ≈ $21.38 Million |
R$-10.51 Million ≈ $-2.06 Million |
-0.096x | -129.36% |
| 2012-12-31 | R$-22.00 Million ≈ $-4.32 Million |
R$-7.23 Million ≈ $-1.42 Million |
0.329x | +61.48% |
| 2011-12-31 | R$-8.76 Million ≈ $-1.72 Million |
R$-1.78 Million ≈ $-349.66K |
0.203x | -82.19% |
| 2010-12-31 | R$-4.06 Million ≈ $-796.84K |
R$-4.64 Million ≈ $-910.45K |
1.143x | -99.77% |
| 2009-12-31 | R$-15.00K ≈ $-2.94K |
R$-7.50 Million ≈ $-1.47 Million |
499.733x | +106719.64% |
| 2008-12-31 | R$-12.22 Million ≈ $-2.40 Million |
R$-5.71 Million ≈ $-1.12 Million |
0.468x | -30.15% |
| 2006-12-31 | R$3.09 Million ≈ $606.12K |
R$2.07 Million ≈ $405.98K |
0.670x | -- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more